56 research outputs found

    Terapia ormonale sostitutiva e osteoporosi postmenopausale

    Get PDF
    SommarioL'osteoporosi postmenopausale è un processo per il quale il tessuto osseo sviluppa una fragilità risultando più suscettibile alle fratture anche per traumi che solitamente non comporterebbero tali eventi. La carenza estrogenica è un punto fondamentale nella patogenesi dell'osteoporosi. La TOS rappresenta un trattamento di scelta nella prevenzione della osteoporosi e delle fratture correlate, soprattutto nei primi anni di postmenopausa

    Developments in dairy cow fertility research.

    Get PDF
    Accurate mass and MS/MS fragmentation data for (a) kynurenine, (b) melatonin, and (c) tryptophan. (TIF 191 kb

    Non-hormonal strategies for managing menopausal symptoms in cancer survivors: an update

    Get PDF
    Vasomotor symptoms, particularly hot flushes (HFs), are the most frequently reported symptom by menopausal women. In particular, for young women diagnosed with breast cancer, who experience premature ovarian failure due to cancer treatments, severe HFs are an unsolved problem that strongly impacts on quality of life. The optimal management of HFs requires a personalised approach to identify the treatment with the best benefit/risk profile for each woman. Hormonal replacement therapy (HRT) is effective in managing HFs but it is contraindicated in women with previous hormone-dependent cancer. Moreover, many healthy women are reluctant to take HRT and prefer to manage symptoms with non-hormonal strategies. In this narrative review, we provide an update on the current available non-oestrogenic strategies for HFs management for women who cannot, or do not wish to, take oestrogens. Since isoflavones have oestrogenic properties and it is not known if they can be safely consumed by women with previous hormonedependent cancer, they were excluded. Selective serotonin reuptake inhibitors/selective serotonin-norepinephrine reuptake inhibitors, as well as other neuroactive agents, some herbal remedies and behavioural strategies are considered

    A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas

    Get PDF
    Background: Prolactinoma, the most common pituitary adenoma, is usually treated with dopamine agonist (DA) therapy like cabergoline. Surgery is second-line therapy, and radiotherapy is used if surgical treatment fails or in relapsing macroprolactinoma. Objective: This study aimed to provide economic evidence for the management of prolactinoma in Italy, using a cost-of-illness and cost-utility analysis that considered various treatment options, including cabergoline, bromocriptine, temozolomide, radiation therapy, and surgical strategies. Methods: The researchers conducted a systematic literature review for each research question on scientific data- bases and surveyed a panel of experts for each therapeutic procedure's specific drivers that contributed to its total cost. Results: The average cost of the first year of treatment was euro2,558.91 and euro3,287.40 for subjects with micro- prolactinoma and macroprolactinoma, respectively. Follow-up costs from the second to the fifth year after ini- tial treatment were euro798.13 and euro1,084.59 per year in both groups. Cabergoline had an adequate cost-utility profile, with an incremental cost-effectiveness ratio (ICER) of euro3,201.15 compared to bromocriptine, based on a willingness-to-pay of euro40,000 per quality-adjusted life year (QALY) in the reference economy. Endoscopic sur- gery was more cost-effective than cabergoline, with an ICER of euro44,846.64. Considering a willingness-to-pay of euro40,000/QALY, the baseline findings show cabergoline to have high cost utility and endoscopic surgery just a tad above that. Conclusions: Due to the favorable cost-utility profile and safety of surgical treatment, pituitary surgery should be considered more frequently as the initial therapeutic approach. This management choice could lead to better outcomes and an appropriate allocation of healthcare resources

    A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells

    Get PDF
    Arginase 1 (Arg1) and indoleamine 2,3-dioxygenase 1\ua0(IDO1) are immunoregulatory enzymes catalyzing the degradation of L-arginine and L-tryptophan, respectively, resulting in local amino acid deprivation. In addition, unlike Arg1, IDO1 is also endowed with non-enzymatic signaling activity in dendritic cells (DCs). Despite considerable knowledge of their individual biology, no integrated functions of Arg1 and IDO1 have been reported yet. We found that IDO1 phosphorylation and consequent activation of IDO1 signaling in DCs was strictly dependent on prior expression of Arg1 and Arg1-dependent production of polyamines. Polyamines, either produced by DCs or released by bystander Arg1+ myeloid-derived suppressor cells, conditioned DCs toward an IDO1-dependent, immunosuppressive phenotype via activation of the Src kinase, which has IDO1-phosphorylating activity. Thus our data indicate that Arg1 and IDO1 are linked by an entwined pathway in immunometabolism and that their joint modulation could represent an important target for effective immunotherapy in several disease settings

    La terapia ormonale sostitutiva oggi: un update

    Get PDF
    Dopo un lungo periodo di uso della terapia ormonale sostitutiva (TOS), basato su risultati globalmente positivi riportati in studi di tipo osservazionale, negli ultimi anni alcuni studi di tipo randomizzato e controllato con placebo (RCTs) hanno mostrato dati differenti ed a volte contrastanti rispetto a quelli di precedenti studi osservazionali. Uno dei motivi che possono spiegare tali differenze è l’età delle pazienti trattate: negli studi osservazionali, l’età media delle donne trattate con TOS è più giovane rispetto a quella delle donne trattate negli RCTs. Così, la risposta dei tessuti nelle donne più giovani potrebbe essere migliore rispetto a quella di donne più anziane. Attualmente, si preferisce iniziare precocemente la somministrazione di HRT e la scelta è di utilizzare le basse dosi all’inizio della terapia

    Impatto della anoressia nervosa a livello scheletrico

    No full text

    Osteoporosi: strategie preventive e terapeutiche

    No full text

    Ruolo degli Omega-3 nella perimenopausa

    No full text
    • …
    corecore